Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna M Milan

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
JIMD Reports|July 5, 2023
Increased prevalence of Parkinson's disease in alkaptonuriaLakshminarayan Ranganath, Milad Khedr, Anna M Milan, et al.
JIMD Reports|September 9, 2020
Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria CentreLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
JIMD Reports|January 14, 2022
Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modellingLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
Metabolites|October 27, 2022
Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of AlkaptonuriaLakshminarayan R Ranganath, Andrew T Hughes, Andrew S Davison, et al.
Clinical Chemistry|February 21, 2019
A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to AlkaptonuriaBrendan P Norman, Andrew S Davison, Gordon A Ross, et al.
Metabolites|August 25, 2022
Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone TreatmentLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
Journal of Inherited Metabolic Disease|September 11, 2019
Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuriaJuliette H Hughes, Peter J M Wilson, Hazel Sutherland, et al.
Human Molecular Genetics|October 11, 2019
Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuriaJuliette H Hughes, Ke Liu, Antonius Plagge, et al.
The American Journal of Clinical Nutrition|February 1, 2022
Vitamin D, vitamin D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patientsSreedhar Subramanian, Jonathan M Rhodes, Joseph M Taylor, et al.
Metabolites|October 27, 2022
Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated AlkaptonuriaBrendan P Norman, Andrew S Davison, Bryony Hickton, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
JIMD Reports|July 5, 2023
Increased prevalence of Parkinson's disease in alkaptonuriaLakshminarayan Ranganath, Milad Khedr, Anna M Milan, et al.
JIMD Reports|September 9, 2020
Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria CentreLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
JIMD Reports|January 14, 2022
Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modellingLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
Metabolites|October 27, 2022
Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of AlkaptonuriaLakshminarayan R Ranganath, Andrew T Hughes, Andrew S Davison, et al.
Clinical Chemistry|February 21, 2019
A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to AlkaptonuriaBrendan P Norman, Andrew S Davison, Gordon A Ross, et al.
Metabolites|August 25, 2022
Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone TreatmentLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
Journal of Inherited Metabolic Disease|September 11, 2019
Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuriaJuliette H Hughes, Peter J M Wilson, Hazel Sutherland, et al.
Human Molecular Genetics|October 11, 2019
Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuriaJuliette H Hughes, Ke Liu, Antonius Plagge, et al.
The American Journal of Clinical Nutrition|February 1, 2022
Vitamin D, vitamin D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patientsSreedhar Subramanian, Jonathan M Rhodes, Joseph M Taylor, et al.
Metabolites|October 27, 2022
Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated AlkaptonuriaBrendan P Norman, Andrew S Davison, Bryony Hickton, et al.
Pageof 4